Intramuscular injection of mRNab‐LNPs reduces CD19+ B and plasma cells in lupus and rheumatoid arthritis mice, significantly alleviating histopathological changes and tissue injuries of skins, kidneys, and joints. Here, CD19 is linked to rheumatoid arthritis.